Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Trastuzumab deruxtecan (DS-8201a)|DRUG: Capecitabine|DRUG: Eribulin|DRUG: Gemcitabine|DRUG: Paclitaxel|DRUG: Nab-paclitaxel
Sponsor: Daiichi Sankyo
Collaborators: Daiichi Sankyo Co., Ltd.|AstraZeneca